NCT07006688View on ClinicalTrials.gov

A Study of an IDH1m Inhibitor in Participants With IDH1-Mutated Malignancies and Hepatic or Renal Impairment

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

July 31, 2028

Study Completion Date

July 31, 2028

Conditions
IDH1-Mutated Malignancies
Interventions
DRUG

Ivosidenib Oral Tablet

500mg Ivosidenib taken orally once daily for continuous 28-day cycles

All Listed Sponsors
collaborator

Institut de Recherches Internationales Servier

OTHER

lead

Servier Bio-Innovation LLC

INDUSTRY